The main focus of this research was to find a cost-effective pathway to synthesize 3,5-disubstituted Δ2-isoxazoline with relatively high percentage yields. 3,5-disubstituted Δ2-isoxazoline contains an isoxazole ring, which is an essential structure in some anti-diabetic medications [1][3]. 3,5 disubstituted Δ2-isoxazoline synthesis relies on a metal catalyst that converts an oxime into the isoxazoline by forming an isoxazole ring. Palladium (II) Chloride is a current metal mediator for this reaction and was tested against Nickel (II) Chloride in varying amounts as well as Lead (II) Acetate.
It was hypothesized that all three metal-mediators will produce 3,5-disubstituted Δ2-isoxazoline. After the reactions were performed to synthesize the 3,5-disubstituted Δ2-isoxazoline, Lead (II) Acetate was deemed to be the most viable and promising option for future research. Nickel (II) Chloride produced traces of 3,5-disubstituted Δ2-isoxazoline, meaning that it is also a feasible option. In future experimentation, both processes will be refined to optimize results. Lead (II) Acetate and Nickel (II) Chloride are also substantially less expensive than Palladium (II) Chloride, which will strengthen their viability for usage in the pharmaceutical industry.
It was hypothesized that all three metal-mediators will produce 3,5-disubstituted Δ2-isoxazoline. After the reactions were performed to synthesize the 3,5-disubstituted Δ2-isoxazoline, Lead (II) Acetate was deemed to be the most viable and promising option for future research. Nickel (II) Chloride produced traces of 3,5-disubstituted Δ2-isoxazoline, meaning that it is also a feasible option. In future experimentation, both processes will be refined to optimize results. Lead (II) Acetate and Nickel (II) Chloride are also substantially less expensive than Palladium (II) Chloride, which will strengthen their viability for usage in the pharmaceutical industry.